The Cure Starts Now has funded $24,388,300 (USD) in pediatric brain cancer research in partnership with the DIPG / DMG Collaborative. This includes 156 grants at over 100 hospitals in 29 countries.




The University of Alabama at Birmingham – $100,000

Amount
$100,000.00
Date
December 2023

Intranasal Delivery of Targeting Nanotherapeutics for DIPG

Funding of PBTCF 2023 - $25,000

Amount
$25,000.00
Date
December 2023

Children's Cancer Institute – $181,736 USD, $281,691 AUD

Amount
$181,736.00
Date
November 2023

Targeting post-translational protein modification to halt Diffuse Intrinsic Pontine Glioma tumorgenicity

Memorial Sloan Kettering Cancer Center – $100,000

Amount
$100,000.00
Date
November 2023

CSF Cell-free Tumor DNA (CSF cfDNA) Liquid Biopsies for Pediatric, Adolescent, and Young Adult Patients with Primary Brain Tumors

University of Colorado Denver – $200,000

Amount
$200,000.00
Date
November 2023

Preclinical assessment of efficacy and specificity of logic-gated CAR-T cell therapy in Diffuse Intrinsic Pontine Glioma

SIOPe DIPG/DMG Registry – $715,852 USD, € 643,014

Amount
$715,852.00
Date
November 2023

Renewal of the European DIPG/DMG Registry

Cincinnati Children's Hospital – $200,000

Amount
$200,000.00
Date
November 2023

Targeting diffuse midline gliomas with innovative T cell immunotherapy

Cincinnati Children's Hospital – $50,000

Amount
$50,000.00
Date
May 2023

Exploring Novel Targets In DIPG

University Medicine Göttingen – $50,000

Amount
$50,000.00
Date
May 2023

Starve the monster: Multi-metabolic treatment strategies for H3.3K27M-mutant DIPG/DMG

Funding of PBTCF 2023 - $25,000

Amount
$25,000.00
Date
January 2023

University of Queensland Diamantina Institute – $100,000

Amount
$100,000.00
Date
November 2022

Innovative Models of the Brain Microenvironment to Identify New Treatments for Medulloblastoma

Erasmus University Medical Center – $432,354

Amount
$432,354.00
Date
November 2022

Development and optimization of targeted radiopharmaceutical therapies for pediatric brain tumors; a world-first translational study. Acronym: TARGET-FIRST

Cincinnati Children's Hospital Medical Center – $60,000

Amount
$60,000.00
Date
November 2022

Targeting Histone Lysine Demethylases to Treat Diffuse Intrinsic Pontine Glioma

Cincinnati Children's Hospital Medical Center – $153,867

Amount
$153,867.00
Date
November 2022

Combining innovative proton radiotherapy with targeted and immune therapies to treat DMG/DIPG

Hunter Medical Research Institute – $232,932

Amount
$232,932.00
Date
November 2022

Enhancing the recruitment of tumor infiltrating lymphocytes to improve responses to DMG therapies